Laura E. Horvath

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Alan P. Venook, Donna Niedzwiecki, Federico Innocenti et al. · Journal of Clinical Oncology · 2016 · 333 citations

Medicine, Oncology, Surgery +16

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma

Mark A. Dickson, M. R. Mahoney, William D. Tap et al. · Annals of Oncology · 2016 · 114 citations · Full text

Medicine, Oncology, Pharmacology +13

Multidisciplinary Care in the Oncology Setting: Historical Perspective and Data From Lung and Gynecology Multidisciplinary Clinics

Laura E. Horvath, Edgardo Yordan, Deepak Malhotra et al. · Journal of Oncology Practice · 2010 · 91 citations · Full text

Medicine, Gynecology, Oncology +9

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma

Robert R. McWilliams, Nathan R. Foster, Michelle R. Mahoney et al. · Cancer · 2017 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17

The relationship between tumor size and stage in early versus advanced ovarian cancer

Laura E. Horvath, Theresa L. Werner, Kenneth M. Boucher et al. · Medical Hypotheses · 2013 · 32 citations

Medicine, Gynecology, Oncology +16